Mathews Journal of Cancer Science

2474-6797

Current Issue volume 5, Issue 1 - 2020

The Role of Temozolomide-Irinotecan in Doxorubicin- Resistant Cell Lines of Recurrent Ewing’s Sarcoma, in A Patient Derived Orthotopic Xenograft (PDOX) with EWS-ERG Fusion and CDKN2A Loss: What Impact the Combination has in Real Life Practice?

Maher Salamoon¹, Mehdi Balti², Bertrand Farnault³, Maher Saifo4, Ali Mahmoud5, Ahmad Khatib6, Manal Daghlawi7, Taisir Husein8, Mazen Kenj9, and Khaled Ghanem10

1Al Bairouni University Cancer Center, department of medical oncology, Damascus University, Damascus, Syria
2Service d’Oncologie, HÔpital Militaire Principal d’Instruction de Tunis, Tunisia 
3Centre Hospitalier Universitaire de Chicas, Alpes du Sud, France
4Department of medical Oncology, Al Bairouni University Cancer Center, Damascus, Syria
5Department of Orthopedic Surgery, Al Bairouni University Cancer Center, Damascus, Syria
6Department of Radiology, Al Bairouni University Cancer Center, Damascus, Syria
7Department of Pathology, Al Bairouni University Cancer Center, Damascus, Syria
8Department of Pathology, Tishreen Hospital, Damascus, Syria
9Department of Cytogenetic, Al Assad Hospital, Damascus, Syria
10Basma Charity for Pediatric Oncology, Damascus, Syria

Corresponding Author
Maher Salamoon, Al Bairouni University Cancer Center, Damascus University Damascus- Syria, Tel: +96-393-377-1086.
Received Date: August 24, 2020
Published Date: October 08, 2020
Copyright: Maher Salamoon, et al. © 2020
Citation: Salamoon M. (2020). The Role of Temozolomide-Irinotecan in Doxorubicin-Resistant Cell Lines of Recurrent Ewing’s Sarcoma, in A Patient Derived Orthotopic Xenograft (PDOX) with EWS-ERG Fusion and CDKN2A Loss: What Impact the Combination has in Real Life Practice?. Mathews J Cancer Sci. (5)1:21

ABSTRACT

Introduction: A patient-derived orthotopic xenograft (PDOX) nude-mouse model and irrespective of genetic profile can help guiding our treatment in progressive and resistant Ewing Sarcoma (ES) patients progressed after Doxorubicin containing regimens. 
Patients and methods: In our study, the PDOX mice established model with ES were divided into two arms once tumor mass exceeded 60 mm3: (1) untreated control (2) irinotecan plus temozolomide (irinotecan: intra-peritoneal injection; temozolomide: orally, daily for 14 days). A similar study was carried out on patients from whom the graft was taken. We have collected data from 35 patients of ES: diagnosed, treated and progressed after the first line chemotherapy. Those patients received oral temozolomide 100mg/m² on days 1 through 5 plus IV irinotecan 10-20 mg/m²/day on days 1 through 5 and day 8 through 12 (repeated every 3-4 weeks).
Results: Irinotecan plus temozolomide was found to be an effective combination when compared to the untreated control (p = 0.022) in mice model where tumor shrinkage was observed on day 10. To assure these findings, we have conducted in part, a study employing both Temozolomide and irinotecan in patients resistant to Doxorubicin containing regimens and demonstrating EWS-ERG fusion and CDKN2A loss. However, the same protocol was used to the same patient where the graft was taken showing not complete concordance between the lab and real practice. 
Conclusion: PDOX is a good model to test a library of drugs on. It shows to be a promising method in several studies and in ours as well. Studies demonstrated that the combination of temozolomide/irrinotecan is effective in ES patients in progression after Doxorubicin resistance. 

KEYWORDS: Ewing Sarcoma; Xenograft; Progression; ERG; EWS; CDKN2A


© 2015 Mathews Open Access Journals. All Rights Reserved.

Creative Commons License
Open Access by Mathews Open Access Journals is licensed under a
Creative Commons Attribution 4.0 International License.
Based On a Work at Mathewsopenaccess.com